Digestery
Longevity supplements › NMN and Aging › Studies

Randomized trial · measured other health measures

A 10-week NR trial in 20 adults with memory problems: no clear thinking gain

Orr and colleagues · GeroScience · 2024

Original title: A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

No difference

Blood NAD+ rose 2.6-fold (p < 0.001). MoCA and other thinking tests stayed stable. Brain blood flow fell in one network (p = 0.013), but not after correction for many tests. Epigenetic age measures fell in exploratory analysis.

The study at a glance

Type of study
Randomized trial
Who or what was studied
20 people · Older adults with mild memory and thinking problems
What was tested
NR rising to 1 g a day for 10 weeks, vs placebo
What it measured
Other health or performance measures
Daily amount
1 g a day
How long
10 weeks
Trial registration
NCT02942888
Who has a stake
Company stake
ChromaDex supplied NR and placebo; a co-author is inventor, ChromaDex adviser and stockholder.
Journal
GeroScience, 2024
Source
PubMed record 37994989. This page is based on the abstract only.

How much this study counts

  • ✓Randomized: people were put into groups by chance, so the groups start out alike.
  • ✓Compared with a placebo, a dummy treatment.
  • –Small: 20 people. Small trials can miss real effects or find chance ones.
  • –Short: 10 weeks. Longer-term effects are unknown.
  • •Measured other health measures, not aging and age-related decline itself.
  • –Company stake: ChromaDex supplied NR and placebo; a co-author is inventor, ChromaDex adviser and stockholder.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related decline

    0

    Not done yet. This is the step that would answer the question.

  2. Trials in people: other measures

    9

    3 benefit, 2 mixed, 4 no difference

    ↑ This study is the ringed dot

  3. Trials in people: lab tests or safety

    7

    4 benefit, 1 mixed, 2 no difference

  4. Population studies

    0

    None among the papers we read.

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    6

    5 benefit, 1 mixed

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does NMN slow aging?”

Not shown in people so far.

Confidence: very low. Based on 29 on-topic papers.

Read the full answer

Of the other 8 papers on the same step: 3 benefit, 2 mixed, 3 no difference. This one found no difference.

Other papers on the same step

See all 29 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The reviewer corrected 2 fields after reading the abstract. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.